Use of a novel index, the A-index, and its associated nomogram to predict overall survival rates after resection of primary hepatocellular carcinoma

Cai, Bin-Bin; Hou, Xiangqing; Zhou, Xiang; Ye, Tingting; Guan, Feifei; Huang, Hanzhang; Bao, Xiaodong; Wang, Weiming

doi:10.1016/j.cca.2019.10.001

Cited by 4 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A nomogram is a simple graphical representation of a statistical prediction model that is frequently applied to patients and has gained popularity among oncologists and patients participating in clinical trials (18)(19)(20)(21)(22)(23). In the current study, we used two nomograms to visually and individually predict the survival of glottic LSCC patients with different clinicopathologic characteristics to help them choose a superior treatment modality.…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy Versus Surgery–Which Is Better for Patients With T1-2N0M0 Glottic Laryngeal Squamous Cell Carcinoma? Individualized Survival Prediction Based on Web-Based Nomograms

Shao

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Radiotherapy Versus Surgery–Which Is Better for Patients With T1-2N0M0 Glottic Laryngeal Squamous Cell Carcinoma? Individualized Survival Prediction Based on Web-Based Nomograms

Shao

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The most common primary liver cancer is PHCC, which is also the main cause of death in people with cirrhosis [16] . However, relative to the previous decades, recent therapeutic improvements have enhanced the survival of current PHCC patients, who receive effective treatment using surgical resection, ablation, trans-arterial chemoembolization, and hepatic arterial infusion chemotherapy plus sorafenib [19,20].…”

Section: Discussionmentioning

confidence: 99%

“…Such as TNM (T: the extent of the primary tumor; N: regional lymph nodes; and M: distant metastases) system or the Child-Pugh-score, which only depends on tumor stage or impairment of liver function, thus can't explain the complexity of liver cancer in cirrhosis [15]. BCLC has been criticized for being too algorithmic to beneficial for clinical use [16]. Besides, The Okuda system has proven to be inadequate for patients with less advanced disease (early HCC) as well as is not bad but far from the excellent predictive ability [17].…”

Section: Agingmentioning

confidence: 99%

Development and validation of a risk score for predicting mortality after resection of primary hepatocellular carcinoma

Zhou

Cai

Hou

et al. 2020

Aging

Self Cite

View full text Add to dashboard Cite

Background: Primary hepatocellular carcinoma (PHCC) has a poor prognosis and high short-term mortality rate, even after resection. Thus, early diagnosis in PHCC cases can help improve quality of life via personalized management strategies. Results: The risk score system (RSS) were classified as low risk (<5 points), medium risk (5–10 points), or high risk (>10 points). The areas under the receiver operating characteristic curves were 0.80 in the training cohort and 0.69 in the validation cohort, which indicated satisfactory prognostic performance. The Hosmer-Lemeshow goodness of fit test ( P >0.05) revealed consistent performance in both groups. The concordance index (C-index: 0.663, 95% CI: 0.618–0.708) revealed excellent discrimination and good calibration in the validation cohort. Conclusions: This simple RSS, which is based on clinical and laboratory data from patients undergoing resection of PHCC, might allow clinicians and medical staff to better manage PHCC. Materials and Methods: A total of 672 PHCC cases were retrospectively obtained from the First Affiliated Hospital of Wenzhou Medical University between January 2007 and February 2015. Cox proportional hazard models were used to identify independent predictors of mortality. Kaplan-Meier curves and the log-rank test were used to examine the relationships between the prognostic factors and overall mortality.

show abstract

“…Second, we only included models with published external validations. We recognize that due to this restriction several recent models (that have not yet been validated) were not included [74,85,86]. Also, models containing prognostic factors not readily available in clinical practice are missing in our analysis.…”

Section: Risk Of Biasmentioning

confidence: 99%

Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients

Beumer

Buettner

Galjart

et al. 2022

European Journal of Surgical Oncology

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Use of a novel index, the A-index, and its associated nomogram to predict overall survival rates after resection of primary hepatocellular carcinoma

Cited by 4 publications

References 32 publications

Radiotherapy Versus Surgery–Which Is Better for Patients With T1-2N0M0 Glottic Laryngeal Squamous Cell Carcinoma? Individualized Survival Prediction Based on Web-Based Nomograms

Radiotherapy Versus Surgery–Which Is Better for Patients With T1-2N0M0 Glottic Laryngeal Squamous Cell Carcinoma? Individualized Survival Prediction Based on Web-Based Nomograms

Development and validation of a risk score for predicting mortality after resection of primary hepatocellular carcinoma

Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients

Contact Info

Product

Resources

About